ZTS News and Press, Zoetis Inc. Class A From 05/03/24

2024-05-03 14:37:00 ET Summary Zoetis is a leader in animal health, focusing on R&D to develop innovative medicines and technologies for pets and livestock. Concerns have arisen about the safety of their drugs, but Zoetis appears confident and reported impressive revenue growt...

2024-05-03 13:49:33 ET Summary The SPDR S&P 500 ETF Trust had a 4.03% loss in April, slightly outperforming Vanguard's Dividend Appreciation Index Fund ETF Shares, -4.13%. The top 15 dividend growth stocks for May 2024 offer an average dividend yield of 1.23% and appear to be ...

2024-05-03 09:00:23 ET Image source: The Motley Fool. Zoetis (NYSE: ZTS) Q1 2024 Earnings Call May 02, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Zoetis (ZTS) Q1 2024 Earnings Call Transcript

2024-05-02 16:56:00 ET Investors were meowing for animal healthcare specialist Zoetis (NYSE: ZTS) on Thursday, following the company's release of its latest quarterly results. These obviously pleased market participants, as the stock's price leaped nearly 6% higher over the course o...

2024-05-02 13:25:26 ET Zoetis Inc (ZTS) Q1 2024 Results Conference Call May 02, 2024 08:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conferen...

2024-05-02 11:40:03 ET More on Zoetis Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment Zoetis: My Favorite Healthcare Stock Right Now Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness Zoetis Non-GAAP EPS of $1.38 beats by $0.04,...

2024-05-02 07:04:10 ET More on Zoetis Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment Zoetis: My Favorite Healthcare Stock Right Now Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness Zoetis Q1 2024 Earnings Preview Zoet...

2024-05-02 07:00:00 ET Summary Value investors have been frustrated as growth stocks have outperformed for the past 15 years. Value investing is a long-term strategy that requires patience and a focus on fundamentals. Three blue-chip stocks, Bristol-Myers, Zoetis, and Monster ...

Reports Revenue of $2.2 Billion, Growing 10%, and Net Income of $599 Million, or $1.31 per Diluted Share, Increasing 9% and 10%, Respectively, on a Reported Basis for First Quarter 2024 Delivers 12% Operational Growth in Revenue and 15% Operational Growth in Adjusted Net Income for First ...

2024-05-01 16:36:45 ET Summary Phibro Animal Health has seen lackluster performance over the past decade, seeing modest sales growth and declining margins. The company recently announced a significant deal with Zoetis, acquiring their medicated feed additive product portfolio for ...